Press Releases Press Releases Year None20192018 December 8, 2019 Stoke Therapeutics Presents Preclinical Data on the Biodistribution, Target Engagement and Safety of STK-001 in Non-Human Primates That Support the Planned Clinical Development of STK-001 for the Treatment of Dravet Syndrome December 7, 2019 Stoke Therapeutics Presents Preclinical Data From Studies of STK-001 That Showed Improvements in Survival and Reductions in Seizure Frequency in a Mouse Model of Dravet Syndrome November 26, 2019 Stoke Therapeutics to Present at Piper Jaffray 31st Annual Healthcare Conference November 25, 2019 Stoke Therapeutics to Present New Preclinical Data on STK-001 at the American Epilepsy Society Annual Meeting November 12, 2019 Stoke Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Update November 5, 2019 Stoke Therapeutics to Present at Upcoming Investor Conferences in November October 16, 2019 Stoke Therapeutics Strengthens Leadership Team With Appointments of Robin A. Walker, J.D., as Senior Vice President, Chief Legal Officer and Joan Wood as Head of Human Resources September 30, 2019 Stoke Therapeutics to Present at 2019 Cantor Global Healthcare Conference September 11, 2019 Stoke Therapeutics Added to Russell 2000 and 3000 Indexes August 20, 2019 Stoke Therapeutics Enrolls First Patient in an Observational Study of Children and Adolescents Living with Dravet Syndrome Pagination Current page 1 Page 2 Next page next › Last page last » Toolkit Print Page Email Alerts Contact IR FAQ
Press Releases Year None20192018 December 8, 2019 Stoke Therapeutics Presents Preclinical Data on the Biodistribution, Target Engagement and Safety of STK-001 in Non-Human Primates That Support the Planned Clinical Development of STK-001 for the Treatment of Dravet Syndrome December 7, 2019 Stoke Therapeutics Presents Preclinical Data From Studies of STK-001 That Showed Improvements in Survival and Reductions in Seizure Frequency in a Mouse Model of Dravet Syndrome November 26, 2019 Stoke Therapeutics to Present at Piper Jaffray 31st Annual Healthcare Conference November 25, 2019 Stoke Therapeutics to Present New Preclinical Data on STK-001 at the American Epilepsy Society Annual Meeting November 12, 2019 Stoke Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Update November 5, 2019 Stoke Therapeutics to Present at Upcoming Investor Conferences in November October 16, 2019 Stoke Therapeutics Strengthens Leadership Team With Appointments of Robin A. Walker, J.D., as Senior Vice President, Chief Legal Officer and Joan Wood as Head of Human Resources September 30, 2019 Stoke Therapeutics to Present at 2019 Cantor Global Healthcare Conference September 11, 2019 Stoke Therapeutics Added to Russell 2000 and 3000 Indexes August 20, 2019 Stoke Therapeutics Enrolls First Patient in an Observational Study of Children and Adolescents Living with Dravet Syndrome Pagination Current page 1 Page 2 Next page next › Last page last »
December 8, 2019 Stoke Therapeutics Presents Preclinical Data on the Biodistribution, Target Engagement and Safety of STK-001 in Non-Human Primates That Support the Planned Clinical Development of STK-001 for the Treatment of Dravet Syndrome
December 7, 2019 Stoke Therapeutics Presents Preclinical Data From Studies of STK-001 That Showed Improvements in Survival and Reductions in Seizure Frequency in a Mouse Model of Dravet Syndrome
November 25, 2019 Stoke Therapeutics to Present New Preclinical Data on STK-001 at the American Epilepsy Society Annual Meeting
November 12, 2019 Stoke Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Update
October 16, 2019 Stoke Therapeutics Strengthens Leadership Team With Appointments of Robin A. Walker, J.D., as Senior Vice President, Chief Legal Officer and Joan Wood as Head of Human Resources
August 20, 2019 Stoke Therapeutics Enrolls First Patient in an Observational Study of Children and Adolescents Living with Dravet Syndrome